Expert Insights

Sponsored
Dr Graff talks about how the CLL treatment landscape has evolved in recent years.
Sponsored
Dr Goy shares highlights of recent innovations in the treatment of patients with MCL.
Michael Schweizer, MD, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.
David O'Malley, MD, highlights promising results from a subgroup analysis of the effect of platinum sensitivity on the efficacy of rucaparib vs chemo for BRCA+, advanced, relapsed ovarian carcinoma.
Dr Krishnan shares findings from a phase 3 trial of teclistamab therapy for relapsed/refractory MM. These data were presented at the 2021 ASCO Annual Meeting.
Efstathios Kastritis, MD, shares findings from the ANDROMEDA study of subcutaneous daratumumab plus standard therapy for AL amyloidosis.
Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.
Saad Usmani, MD, shares findings from the CARTITUDE-1 study of ciltacabtagene autoleucel therapy for patients with R/R MM. These data are being presented at the 2021 ASCO Annual Meeting.

Interviews

Michael Schweizer, MD, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.
Ezra Cohen, MD, FRCPSC, FASCO, San Diego Moores Cancer Center, discusses personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer, presented at the 2021 ASCO Annual Meeting.
Richard M. Stone, MD, recently shared updates on the treatment of high-risk AML at Miami Cancer Institute’s Second Summit of the Americas on Immunotherapies for Hematologic Malignancies.
Javier Cortes, MD, PhD, International Breast Cancer Center, discusses the role of immunotherapy in the first line treatment of metastatic triple-negative breast cancer, presented at the 2021 Great…

Webcasts

Sponsored
In this video, Dr Danilov discusses the use of acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
Sponsored
Dr Graff talks about how the CLL treatment landscape has evolved in recent years.
Sponsored
Dr Goy shares highlights of recent innovations in the treatment of patients with MCL.
Michael Schweizer, MD, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.

Resources

Detailed information about the presentation, diagnosis, staging, prognosis, and treatment of all types of childhood NHL and lymphoproliferative disease.
Non-Hodgkin lymphoma treatment options include chemotherapy, radiation, targeted therapy, plasmapheresis, surveillance, stem cell transplant, and surgery. Get comprehensive information on Non-Hodgkin…
Chronic myelogenous leukemia treatments include tyrosine kinase inhibitors, high-dose therapy with allogeneic transplantation, and other medications. Get detailed information about chronic…
Breast cancer is the most common cancer in pregnant and postpartum women and occurs in about 1 in 3,000 pregnant women. The average patient is between the ages of 32 years and 38 years. Because many…

Debates and Roundtables

In the third part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss notable advancements in the standard treatment of T-cell lymphoma.
In the second part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the background, findings, and importance of the ECHELON-2 clinical trial.
In the first part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the challenges of treating patients with T-cell lymphoma.
In the second installment of this roundtable discussion, experts sat down with Oncology Learning Network to discuss use of liquid biopsies to detect treatment resistance in lung cancer, areas for…
Stay in the know.
OncNet Newsletter